Author: Ravi Shankar

Mount Logan Management LLC has signed a definitive agreement to succeed Alternative Fund Advisors, LLC as investment adviser to the AFA Asset Based Lending Fund, which will bring Mount Logan’s interval fund assets under management to approximately $460 million.

Once the transaction closes, the Fund will be renamed Mount Logan Asset Based Lending Fund and will continue its focus on asset-based and specialty finance investing. The Fund’s shareholders will gain access to a larger asset management platform and increased direct origination of lending opportunities.

Mount Logan currently expects the transaction will be immediately accretive to its FRE¹ upon closing.

The transaction is expected to close in Q1 2027, subject to regulatory and shareholder approvals.

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) — Mount Logan Capital Inc. (Nasdaq: MLCI) (“Mount Logan”) today announced that Mount Logan Management LLC, its wholly owned registered investment adviser (“MLM”), has entered into a definitive agreement to become the new investment adviser to the AFA Asset Based Lending Fund (“Fund”) (the “Transaction”). In connection with the Transaction, MLM and Alternative Fund Advisors, LLC (“AFA”), the Fund’s current investment adviser, have entered into an Asset Purchase Agreement (the “APA”) pursuant to which MLM will acquire certain business records, intellectual property, and goodwill of AFA related to the management of the Fund.

The Fund will be MLM’s second evergreen credit interval fund, complementing MLM’s Opportunistic Credit Interval Fund. Together, the two funds establish a scaled, differentiated product suite for the private wealth channel, spanning asset-based specialty finance and opportunistic corporate credit.

Upon closing, the Fund will be renamed Mount Logan Asset Based Lending Fund. It will continue to provide access to a broadly diversified range of asset-based lending and specialty finance credits. Fund shareholders are expected to benefit from MLM’s scale, resources and extensive in-house origination capability. The Fund manages approximately $230 million in assets from a wide range of investors, particularly those interested in diversifying their fixed income portfolios.

The Transaction will bring MLM’s combined interval fund assets to approximately $460 million. Mount Logan currently expects the Transaction will be immediately accretive to FRE upon closing.

Ted Goldthorpe, CEO of Mount Logan, said, “This is a significant milestone in the build-out of Mount Logan’s evergreen credit platform and reflects our continued discipline in acquiring permanent and semi-permanent capital vehicles. The Fund broadens MLM’s core products, extends our distribution reach in the private wealth channel, and is highly complementary to our Opportunistic Credit Interval Fund. It also provides a differentiated, institutionally managed asset-based lending strategy that leverages the credit sourcing and underwriting capabilities of the broader Mount Logan and BC Partners Credit platform.”

“We are excited about this next phase in the evolution of the AFA Asset Based Lending Fund,” said Marco Hanig, CEO of Alternative Fund Advisors. “We expect the resources and investment expertise of the Mount Logan platform to enhance the Fund’s strategy through direct origination alongside third-party origination channels. We look forward to partnering with Ted and the Mount Logan team in the Fund’s next phase of growth.”

About Mount Logan Capital Inc.
Mount Logan Capital Inc. (“MLCI”) is an integrated alternative asset management and insurance solutions firm focused on generating durable, fee-based revenue and long-term value creation. MLCI leverages differentiated investment strategies alongside permanent insurance capital to deliver attractive, risk-adjusted returns across market cycles.

Through its subsidiaries, MLM and Ability Insurance Company, MLCI manages and invests across private and public credit markets in North America and operates an insurance platform that provides long-duration liabilities to support its credit investment strategies. This integrated platform is designed to provide stable earnings, downside protection, and a low risk of principal impairment through the credit cycle.

As of June 30, 2026, MLCI had over $2 billion in assets under management.

About AFA Asset Based Lending Fund
The AFA Asset Based Lending Fund is an interval fund launched on June 30, 2021 that seeks high current income by investing in a diversified portfolio of asset-based loans across specialty finance, real estate, and other private credit niches. The Fund offers daily subscriptions at net asset value and conducts quarterly repurchase offers subject to a limit of 5% of the Fund’s net assets. As of September 30, 2026, the Fund had approximately $230 million in net assets across 650 underlying investments.

About Alternative Fund Advisors, LLC
Alternative Fund Advisors provides financial advisors and family offices with efficient and convenient access to private investments through interval funds.

Approvals and Timing
Additional details regarding the Transaction are available on a Current Report on Form 8-K that was filed by Mount Logan with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov. The Transaction has been unanimously approved by the AFA Asset Based Lending Fund’s board of trustees, as well as Mount Logan’s board of directors. The change in investment adviser and the new investment management agreement are subject to approval by a majority of the Fund’s shareholders, as well as customary regulatory approvals. The Fund intends to file a proxy statement with the SEC shortly following this announcement and thereafter commence the shareholder vote solicitation. Subject to the requisite approvals, closing is expected to occur in Q1 2027.

Advisors
Dechert LLP is serving as legal counsel to Mount Logan. Faegre Drinker Biddle & Reath LLP is serving as legal counsel to the AFA Asset Based Lending Fund and its Board of Trustees. Reitler Kailas & Rosenblatt LLP is serving as legal counsel and Berkshire Global Advisors is serving as financial advisor to AFA.

DISCLOSURES
Estimates and Assumptions
This press release includes unaudited financial and business projections. These projections, and their underlying assumptions, are inherently unpredictable and undue reliance should not be placed thereon.

These estimates reflect internal financial models that Mount Logan uses in connection with its strategic planning and are based on numerous variables and assumptions made by Mount Logan’s management with respect to industry performance, general business, economic, regulatory and financial conditions and other future events, as well as matters specific to Mount Logan’s businesses, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Mount Logan’s management. As a result, these estimates constitute forward-looking statements and are subject to many risks and uncertainties that could cause actual results to differ materially from these projections. Please carefully consider “Cautionary Statement Regarding Forward-Looking Statements” below. There can be no assurance that these estimates will be realized or that actual results will not be significantly different than projected.

The inclusion of these estimates in this press release should not be regarded as an indication that Mount Logan or any of its affiliates, advisors, officers, directors or representatives considered or considers such estimates to be necessarily predictive of actual future events, and these estimates should not be relied upon as such. The inclusion of these estimates herein should not be deemed an admission or representation by Mount Logan that its management views these estimates as material information.

Certain of the estimates and projections set forth herein may be considered non-GAAP financial measures, including FRE. There are limitations inherent in non-GAAP financial measures, because they exclude charges and credits that are required to be included by generally accepted accounting principles in the United States (“GAAP”). Non-GAAP measures should not be considered in isolation from, or as a substitute for, financial information presented in compliance with GAAP, and non-GAAP financial measures used by Mount Logan may not be comparable with similarly titled amounts used by other companies. No reconciliation of these non-GAAP measures was created or used in connection with preparing the estimates included herein.

Cautionary Statement Regarding Forward-Looking Statements
This press release, and oral statements made from time to time by representatives of Mount Logan, AFA or AFA Asset Based Lending Fund may contain statements of a forward-looking nature relating to future events within the meaning of applicable U.S. and Canadian securities laws. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “could,” “continue,” “estimate,” “expects,” “intends,” “will,” “should,” “may,” “plan,” “predict,” “project,” “would,” “forecasts,” “seeks,” “future,” “proposes,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions). Forward-looking statements are not statements of historical fact and reflect Mount Logan’s or AFA’s current views about future events. Such forward-looking statements include, without limitation, statements about the expected timing and benefits of the transaction, the expected increase in FRE and accretive nature of the transaction between AFA and Mount Logan, future financial and operating results, Mount Logan’s or the Fund’s plans, objectives, expectations and intentions regarding our business strategy and plans, and other statements that are not historical facts, including but not limited to the inability to complete and recognize the anticipated benefits of the transaction on the anticipated timeline or at all, including as a result of a failure to obtain the required shareholder or regulatory approvals, changes in the Fund’s assets under management, purchase price adjustments, unexpected costs related to the transaction, future results of operations, projected cash flow and liquidity, business strategy, shareholder liquidity and the payment of dividends to shareholders of Mount Logan or the Fund, and other plans and objectives for future operations. No assurances can be given that the forward-looking statements contained in this press release will occur as projected, and actual results may differ materially from those projected. Forward-looking statements are based on current expectations, estimates and assumptions that involve a number of risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those projected. Forward-looking statements are based on the estimates and opinions of management at the time the statements are made. Readers should carefully review the statements set forth in the reports, which Mount Logan and the Fund have filed or will file from time to time with the SEC or on SEDAR+ and any risk factors contained in such reports, including the section titled “Risk Factors” in Mount Logan’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 19, 2026. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.

Each of Mount Logan, AFA and the Fund does not undertake any obligation, and expressly disclaims any obligation, to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Any discussion of past performance is not an indication of future results. Investing in financial markets involves a substantial degree of risk. Investors must be able to withstand a total loss of their investment. The information herein is believed to be reliable and has been obtained from sources believed to be reliable, but no representation or warranty is made, expressed or implied, with respect to the fairness, correctness, accuracy, reasonableness or completeness of the information and opinions. The information contained on the website of Mount Logan or the Fund is not incorporated by reference into this press release. Neither Mount Logan, AFA nor the Fund is responsible for the contents of third-party websites.

No Offer or Solicitation
This press release is not, and under no circumstances is it to be construed as, a prospectus or an advertisement and the communication of this release is not, and under no circumstances is it intended to be and does not constitute an offer to sell or the solicitation of an offer to purchase any securities in MLCI, the Fund, or in any fund or other investment vehicle in any jurisdiction pursuant to the proposed transactions or otherwise, nor is it intended to solicit a proxy from any shareholder of the Fund.

Additional Information and Where to Find It
Additional information regarding the proposed change in investment adviser to MLM will be presented in a proxy statement that will be provided to the Fund’s shareholders at a meeting of the Fund’s shareholders.

The proxy statement has yet to be filed with the SEC. After the proxy statement is filed with the SEC, it may be amended or withdrawn at any time. When available and definitive, as applicable, the Fund’s shareholders are encouraged to review the proxy statement on the SEC website at www.sec.gov or on the Fund’s website at www.alternativefundadvisors.com.

INVESTORS HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION. 

Participants in the Solicitation
The AFA Asset Based Lending Fund, MLCI, MLM, AFA, and their respective directors/trustees, officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the shareholders of the Fund in connection with the proposed Transaction. Information regarding the persons who may be deemed participants in such solicitation will be set forth in the proxy statement relating to the proposed transaction when it is filed with the SEC. Shareholders may obtain additional information regarding the interests of the participants in the solicitation of proxies in connection with the proposed transaction by reading the proxy statement when it becomes available.

AFA  ASSET BASED LENDING FUND DISCLOSURES

The Fund’s quarterly repurchase offer is expected to be 5% of net assets, but may range from 5% to 25% subject to approval by the Fund’s Board of Trustees. If a repurchase offer is oversubscribed, shareholders will only be able to have a portion of their shares repurchased. There is no guarantee that shareholders will be able to tender their shares when or in the amount they desire.

Investors should carefully consider the Fund’s investment objectives, risks, charges, and expenses before investing. This information is included in the Fund Prospectus which can be accessed at https://alternativefundadvisors.com or by calling 800-452-6804. Read the prospectus carefully before you invest.

An investment in the Fund involves a high degree of risk. An investment in the Fund should be viewed only as part of an overall investment program and you should invest only if you can sustain a complete loss of your principal. An investment in the Fund is subject to, among others, the following risks:

• The Fund is a “non-diversified” management investment company registered under the Investment Company Act of 1940, as amended;
• Shares of the Fund are not listed on any securities exchange and it is not anticipated that a secondary market for shares will develop;
• Shares are appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment;
• Although the Fund will offer quarterly liquidity through a quarterly repurchase process, there is no assurance that an investor will be able to sell or otherwise liquidate all their shares tendered during a quarterly repurchase offer; and
• The Fund’s investment in private credit companies is speculative and involves a high degree of risk, including the risk associated with leverage.

AFA Asset Based Lending Fund is distributed by Foreside Fund Services, LLC. Foreside Fund Services is not affiliated with Mount Logan Capital Inc.

Contacts:
Mount Logan Capital Inc.
650 Madison Ave, Floor 3
New York, NY 10022
mlc.ir@mountlogan.com

Andrew Berger
SM Berger & Company
andrew@smberger.com

______________________________
¹ FRE is a non-GAAP financial measure that Mount Logan believes provides valuable perspective on its business results, but it should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Estimated FRE contribution is a forward-looking statement based on management’s current expectations and assumptions. Actual results depend on a number of factors, many of which are outside Mount Logan’s control, and may differ materially from these estimates. See “Estimates and Assumptions” for additional information.

MARLBOROUGH, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) — IPG Photonics Corporation (Nasdaq: IPGP) will release its third quarter 2026 financial results before the market opens on Tuesday, November 3, 2026. The Company will hold a conference call to review these results at 10:00 a.m. ET on the same day. To access the call, please dial 877-407-6184 in the United States or 201-389-0877 internationally. A live webcast of the call will also be available and archived in the investor relations section of the Company’s website at investor.ipgphotonics.com.

About IPG Photonics Corporation

Innovation is at the heart of IPG Photonics. As a global leader in laser technology, we apply light to transform the world. From manufacturing to medical and beyond, our breakthrough laser solutions power our customers’ success and expand what’s possible. Discover more at www.ipgphotonics.com.

Contact

Eugene Fedotoff
Senior Director, Investor Relations
IPG Photonics Corporation
508-597-4713
efedotoff@ipgphotonics.com

REDWOOD CITY, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolve 308, a global Phase 3 clinical trial evaluating zoldonrasib, an investigational, RAS(ON) G12D-selective inhibitor, in combination with standard of care pembrolizumab plus chemotherapy as a first-line treatment in adult patients with metastatic RAS G12D non-squamous non-small cell lung cancer (NSCLC).

“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed encouraging preliminary antitumor activity and a favorable safety profile, providing strong clinical rationale for the Phase 3 RASolve 308 trial. This study, along with additional registrational trials underway in multiple tumor types across our pipeline of differentiated RAS(ON) inhibitors, underscores our commitment to establishing RAS(ON) inhibition as a new standard of care and backbone for treating patients with RAS-addicted cancers,” said Alan Sandler, M.D., chief development officer of Revolution Medicines.

RASolve 308 (NCT07777822) is a global, randomized, double-blind Phase 3 trial evaluating zoldonrasib in combination with pembrolizumab and platinum-based chemotherapy doublet compared with placebo in combination with pembrolizumab and platinum-based chemotherapy doublet in the treatment of adult patients with previously untreated metastatic RAS G12D non-squamous NSCLC. The primary endpoint is progression-free survival. Key secondary endpoints include overall survival, objective response rate, duration of response, safety and tolerability, and patient-reported outcomes.

About Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%–85% of all lung cancers, with more than 229,000 people diagnosed in the U.S. each year.^1,2 Despite treatment advancements, NSCLC remains a leading cause of cancer-related mortality worldwide, primarily due to its late-stage diagnosis and limited response to conventional therapies. RAS mutations are among the most common oncogenic drivers in NSCLC, occurring in approximately 30% of cases. Of those, RAS G12D mutations occur in about 4% of NSCLC cases.³

About Zoldonrasib
Zoldonrasib is an investigational, oral, RAS(ON) G12D-selective covalent, tri-complex inhibitor that binds to cyclophilin A, creating a binary complex that binds to and inhibits the active, oncogenic RAS(ON) G12D mutation. RAS G12D is the most prevalent RAS mutation, accounting for approximately 29% of all RAS-driven cancers.⁴ Across tumor types, approximately 61,000 new patients with RAS G12D cancers are estimated annually in the U.S., with no targeted therapy currently approved for these patients.⁴ Zoldonrasib is currently being investigated as a monotherapy and in combination with other therapies, including with Revolution Medicines’ RAS(ON) multi-selective inhibitor RASONQUE^TM (daraxonrasib), as well as standard of care regimens in lung and gastrointestinal cancers.

About Revolution Medicines, Inc.
Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the broad potential of RAS(ON) inhibition, including in lung and gastrointestinal cancers; treatment practices for lung cancer; the company’s development strategy; and progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company’s candidates being studied.

Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” “believe,” “estimate,” “expect,” “plan,” “potential,” “project,” “up to,” “will” and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 5, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contacts 

Media
media@revmed.com  

Investors
investors@revmed.com 

References

¹ American Cancer Society. What Is Lung Cancer? Available at: https://www.cancer.org/cancer/types/lung-cancer/about/what-is.html. Accessed August 2026.
² American Cancer Society. Key Statistics for Lung Cancer. Available at: https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html. Accessed August 2026.
³ Reita D, Pabst L, Pencreach E, et al. Direct targeting KRAS mutation in non-small cell lung cancer: Focus on resistance. Cancers (Basel). 2022;14(15):1321. doi:10.3390/cancers14051321
⁴ Estimated using tumor mutation frequencies from Foundation Medicine Insights March 2022 and scaled to estimated patient numbers using cancer incidence from ACS Cancer Facts and Figures 2023.

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) — The Nasdaq Stock Market^® (Nasdaq: NDAQ) announced that the trading halt in CN Healthy Food Tech Group Corp. (Nasdaq: UCFI and UCFIW) will continue. Nasdaq has requested additional information from the company, and trading will remain halted until the company has satisfied Nasdaq’s request for information. Trading in the company’s common stock and warrants was halted on October 1, 2025 at 11:28:10 Eastern Time.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotes^SM on the Nasdaq^® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

Nasdaq Contact:

Nasdaq MarketWatch
dl-NasdaqMarketWatch@nasdaq.com

NDAQO

• Investor webcast at 4:30 p.m. ET on October 22 to discuss ORIGIN 3 final efficacy results for TRUTAKNA™ (atacicept-vymj) featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026
• Q3 2026 financial results investor webcast scheduled at 4:30 p.m. ET on November 5

BRISBANE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that it will host two upcoming investor webcasts to discuss ORIGIN 3 final efficacy results as presented at the American Society of Nephrology (ASN) Kidney Week 2026 and its third quarter 2026 financial results and business updates.

ASN Kidney Week 2026 Investor Webcast

The Company’s management team will host a live investor webcast at 4:30 p.m. ET on Thursday, October 22, 2026, to discuss the final efficacy analysis from the ORIGIN 3 clinical trial of TRUTAKNA in IgA nephropathy (IgAN), which will be featured in a late-breaking oral presentation during the opening plenary session of ASN Kidney Week 2026.

Participants can register for the company’s webcast here. A replay of the webcast will be available for 90 days and can be accessed by visiting the “News & Events” section of the Investors page of the Company’s website.

Joining the Company’s management team will be Jonathan Barratt, PhD, FRCP, Mayer Professor of Renal Medicine at the University of Leicester. A live question and answer session will follow the presentation.

About Jonathan Barratt, PhD, FRCP: Dr. Barratt leads the Renal Research Group within the College of Life Sciences, University of Leicester. His research is focused on a bench-to-bedside approach to improving the understanding of the pathogenesis of IgAN, a common global cause of kidney failure. Dr. Barratt is the IgAN Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases, and a member of the steering committee for the International IgAN Network. He works closely with pharmaceutical companies interested in new treatments for IgAN, is Chief Investigator for a number of international randomized controlled Phase 2 and 3 clinical trials in IgAN, and was a member of the U.S. Food and Drug Administration and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgAN Workgroup.

Third Quarter 2026 Financial Results Investor Webcast

The Company’s management team will host a live investor webcast at 4:30 p.m. ET on Thursday, November 5, 2026, to discuss the third quarter 2026 financial results and business updates.

Participants can register for the webcast here. A replay of the webcast will be available for 90 days and can be accessed by visiting the “News & Events” section of the Investors page of the Company’s website.

TRUTAKNA (atacicept-vymj) Indication

TRUTAKNA (atacicept-vymj) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Important Safety Information

Contraindications: TRUTAKNA is contraindicated in patients with serious hypersensitivity to atacicept-vymj or any excipients of TRUTAKNA.

Warnings and Precautions

Immunosuppression and Increased Risk of Infections: TRUTAKNA suppresses the immune system by reducing antibody production, which may increase the risk of infections. Patients with chronic infection or recurring infections may have an increased risk of serious infection. In clinical trials, infections were reported in 32% of TRUTAKNA patients compared with 28% of placebo patients.

Before initiating TRUTAKNA, assess patients for active infections. Delay TRUTAKNA administration in patients with active infection until the infection resolves or is adequately treated. Monitor patients for signs and symptoms of infection during treatment with TRUTAKNA. If a serious infection develops, consider interrupting TRUTAKNA until the infection is controlled.

The concomitant use of TRUTAKNA and other immune-modulating therapies has not been evaluated. Concomitant use of TRUTAKNA with drugs that affect the immune system, including systemic corticosteroids, may increase the risk of infection.

Immunosuppression and Immunization Risk: TRUTAKNA may interfere with the immune response to vaccines and increase the risk of infection from live vaccines. Prior to initiating treatment with TRUTAKNA, complete all age-appropriate immunizations. Live vaccines are not recommended within 30 days prior to initiation or during treatment with TRUTAKNA as safety of coadministration has not been established.

Adverse Reactions: The most common adverse reactions (≥5%) in patients treated with TRUTAKNA and placebo, respectively, were infections (32% vs 28%) and local administration reactions (30% vs 5%). The most common infection was upper respiratory tract infection (12% vs 9%), and the most common local administration reactions were injection site reaction (19% vs 2%) and injection site erythema (6% vs 1%).

Use in Specific Populations

Pregnancy: Available data on TRUTAKNA used in pregnant women exposed during clinical trials are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Based on the mechanism of action, TRUTAKNA may cause immunosuppression in the in utero-exposed infant. Consider the potential clinical impact of TRUTAKNA exposure in infants exposed in utero. Pregnant women exposed to TRUTAKNA, or their healthcare provider, should report TRUTAKNA exposure by calling 1-833-633-8372.

Pediatric Use: The safety and effectiveness of TRUTAKNA in pediatric patients have not been established.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Vera Therapeutics at 1-833-MED-VERA or medinfo@veratx.com.

Please see full Prescribing Information for additional Important Safety Information.

About TRUTAKNA

TRUTAKNA, a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor, is a soluble recombinant fusion protein containing the human transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines BAFF and APRIL.¹ BAFF and APRIL are key cytokines that activate B cells and drive IgAN pathophysiology. In IgAN, activated B cells produce both the antigen and associated antibodies that result in the production of damaging IgA immune complexes. The overlapping roles of BAFF and APRIL in activating B cells support the potential for TRUTAKNA as a disease-modifying therapy.² TRUTAKNA is self-administered as an at-home, small-volume (1 ml), 150 mg once-weekly autoinjector.

TRUTAKNA TRU SUPPORT™ Patient Support Program

We are dedicated to ensuring that eligible IgAN patients can access the first approved therapy that targets both BAFF and APRIL. TRUTAKNA TRU SUPPORT, our patient support program, offers insurance coverage assistance, financial assistance options for eligible patients, and educational resources designed to support patient access and care. Eligible commercially insured patients may pay as little as $0 out of pocket through our copay assistance program. More information will be available on www.veratx.com.

About IgAN

IgAN is a serious, progressive, immune-mediated kidney disease and a leading cause of chronic kidney disease and kidney failure worldwide.^2,3 Approximately 2.5 adults per 100,000 worldwide are diagnosed with IgAN each year, most often between 30 and 40 years of age.^4,5 Over time, IgAN can lead to irreversible kidney damage and may ultimately require dialysis or kidney transplantation. At least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis.³

About Vera Therapeutics

Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA (atacicept-vymj), a BAFF and APRIL inhibitor indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.

Forward-looking Statements

Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential for TRUTAKNA as a disease-modifying therapy; and the plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. Words such as “anticipate,” “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, risks related to commercial launch, market acceptance, and payer coverage, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

References

1. TRUTAKNA™ [Prescribing Information]. Brisbane, CA: Vera Therapeutics, Inc; July 2026

2. Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol. 2024;3:1346769. Published 2024 Feb 1. doi:10.3389/fneph.2023.1346769

3. Pitcher D, Braddon F, Hendry B, et al. Long-Term Outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738. doi:10.2215/CJN.0000000000000135

4. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414-430. doi:10.1093/ndt/gfq665

5. Jarrick S, Lundberg S, Welander A, et al. Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study. J Am Soc Nephrol. 2019;30(5):866-876. doi:10.1681/ASN.2018101017

For more information, please contact:
Investor Contact:
Joshua Qin
Vera Therapeutics
650-360-6978
ir@veratx.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

DENVER, Oct. 20, 2026 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced it will release its 2027 fiscal first quarter financial results on Tuesday, November 3, 2026, after market close. In conjunction, the Company will host a conference call to review the results at 5 p.m. E.T.

Conference Call Details
A live audio webcast of the call will be available on the Company’s website, https://investor.innovage.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for a limited time. To access the call by phone, please go to this link (registration link), for dialing instructions and a unique access pin. We encourage participants to dial into the call fifteen minutes ahead of the scheduled start time.

About InnovAge
InnovAge is a market leader in managing the care of high-cost, frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE). With a mission of enabling older adults to age independently in their own homes for as long as safely possible, InnovAge’s patient-centered care model is designed to improve the quality of care its participants receive while reducing over-utilization of high-cost care settings. InnovAge believes its PACE healthcare model is one in which all constituencies — participants, their families, providers and government payors — “win.” As of June 30, 2026, InnovAge served approximately 8,230 participants across 20 centers in six states. https://www.innovage.com/.

Investor Contact:
Ryan Kubota
rkubota@innovage.com

Media Contact:
press@innovage.com

This press release was published by a CLEAR® Verified individual.

The new Smithfield, Rhode Island facility provides additional hangar capacity for Merlin’s expanding fleet, including the addition of a Beechcraft King Air and L-39 Albatros, and flight test program

BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) — Merlin, Inc. (NASDAQ: MRLN), an aerospace and defense technology company building the operating system of record for autonomous flight, today announced that it has moved its U.S. flight operations to North Central State Airport in Smithfield, Rhode Island. The move provides the additional hangar capacity and operational flexibility needed to support Merlin’s expanding aircraft fleet and growing flight testing requirements. As part of the transition to North Central, the company has concluded its flight operations at Quonset State Airport.

Merlin’s expanding fleet includes a Beechcraft King Air, which was first flown by the Merlin Pilot this month, as well as an L-39 Albatros, the company’s first owned jet aircraft. The L-39 represents an important opportunity to extend the Merlin Pilot autonomy platform toward tactical mission profiles and other high performance military missions. Together with Merlin’s work on the Cessna 208 Caravan and Lockheed Martin C-130J Super Hercules, these platform integrations give the company a representative range of airframes spanning single- and twin-engine platforms, a military transport aircraft, and a jet. This breadth enables Merlin to mature a versatile autonomy platform across aircraft types and missions its customers operate every day.

“Flight testing is central to everything we do, and our infrastructure needs to grow alongside our technology and aircraft fleet,” said Matt George, CEO and founder of Merlin. “North Central State Airport gives us the space and operational flexibility we need for our evolving flight test programs, while bringing these critical operations closer to our Boston headquarters and growing team. This move reflects the momentum Merlin has built and our continued investment in the region.”

Merlin’s broader vision is to help establish the greater Boston area as a hub for aviation autonomy. Expanding the region’s hangar, flight testing, and operational capacity is critical to building that ecosystem and advancing the next generation of autonomous aircraft. The company’s growing regional presence is also expected to support continued job creation and provide access to the Northeast’s deep pool of aerospace, engineering, and technology talent. That talent base will be essential as Merlin expands its team and develops increasingly sophisticated autonomous flight capabilities.

About Merlin
Merlin is an aerospace and defense technology company building the operating system of record for autonomous flight. Through a first-principles approach, the company is redefining what’s possible across aviation, aerospace, and defense with the goal of delivering full-stack autonomy for any aircraft, military or civilian, from takeoff to touchdown. The Merlin Pilot system powers a growing range of aircraft and mission profiles, proven through hundreds of autonomous flights from test facilities across the globe. With $100M+ total in IDIQ contract ceiling value under its C-130J autonomy program with USSOCOM, Merlin is advancing American leadership in autonomous aviation. To learn more, visit www.merlinlabs.com or follow us on X @merlinaero.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact should be considered forward-looking statements, including without limitation statements regarding: the expected benefits of the move to North Central State Airport; our ability to support our expanding aircraft fleet and growing flight testing requirements; our ability to mature our autonomy platform across aircraft types and missions; our vision to establish the greater Boston area as a hub for aviation autonomy and the expected related job creation and access to talent; and our goal of delivering full-stack autonomy for any aircraft. These forward-looking statements are based on our current expectations, assumptions, and projections about future events and trends. These forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, including without limitation the risks and uncertainties detailed under the section entitled “Risk Factors” of our final prospectus, dated May 13, 2026, filed with the SEC on May 13, 2026, and our subsequently filed Quarterly Reports on Form 10-Q, which are available from the SEC. Except as required by applicable law, we undertake no obligation to update any of these forward-looking statements after the date of this press release. 

Media Contacts
Kristen Georgette
617-842-6064
merlin@pluckpr.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/64f0e2e2-8728-4711-a72a-5553bcb3c82a

SCOTTSDALE, Ariz., Oct. 20, 2026 (GLOBE NEWSWIRE) — Black Rock Coffee Bar, Inc. (Nasdaq: BRCB) (“Black Rock Coffee Bar”) today announced that the Company plans to host a conference call to discuss its third quarter 2026 financial results on November 10^th, 2026, at 5:00 p.m. Eastern Time.

The conference call can be accessed live over the phone by dialing 1-877-704-4453 or for international callers, 1-201-389-0920. A live webcast of the conference call will also be available in the investor relations section of Black Rock Coffee Bar’s website, ir.br.coffee.

A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13762671. The replay will be available until Tuesday, November 24, 2026.

About Black Rock Coffee Bar

Black Rock Coffee Bar is a high-growth operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by our engaging baristas. Black Rock Coffee Bar was founded in 2008 in Beaverton, Oregon. What started as a single 160 square foot coffee bar in 2008 is now one of the fastest growing beverage companies in the United States by revenue and the largest fully company-owned coffee retailer in the country, with more than 210 locations spanning seven states from the Pacific Northwest to Texas.

Investor Contact
Will MacIntosh
investors@br.coffee
(541) 208-1860

Media Contact
Jessica Wegener-Beyer
media@br.coffee

VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) — Tree Island Steel Ltd. (“Tree Island” or the “Company“) (TSX: TSL) is pleased to announce that it will report its third quarter 2026 financial results for the period ended September 30, 2026, after market hours on Tuesday, November 10, 2026.

About Tree Island Steel

Tree Island Steel, headquartered in Richmond, British Columbia, since 1964, through its operating facilities in Canada and the United States, produces wire products for a diverse range of industrial, residential construction, commercial construction and agricultural applications. Its products include galvanized wire, bright wire; a broad array of fasteners, including packaged, collated and bulk nails; stucco reinforcing products; concrete reinforcing mesh; fencing and other fabricated wire products. The Company markets these products under the Tree Island®, Halsteel®, K-Lath®, TI Wire®, Tough Strand® and ToughPanel™ brand names.

For more information, please contact:

Ali Mahdavi
Investor Relations & Capital Markets
(416) 962-3300
email: amahdavi@treeisland.com 
Website: www.treeisland.com 

Mercedes-Benz dealerships across the U.S. now have access to NETSOL’s Transcend Retail platform which keeps each deal intact as buyers move between online and in-store

ENCINO, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) — NETSOL Technologies, Inc. (Nasdaq: NTWK), a provider of AI-enabled solutions and services powering OEMs, dealerships and financial institutions to sell, finance and lease assets, today announced that Mercedes-Benz USA has approved NETSOL as a digital retail provider for Mercedes-Benz dealerships. This opens the brand’s dealer network to Transcend Retail, NETSOL’s digital retail platform.

The platform gives buyers a single, continuous purchase experience, from configuring a vehicle and valuing a trade-in to reviewing transparent payment and finance options and completing the transaction, whether that happens online, in the showroom or across both. Buyers and dealership teams work on the same deal in parallel, so either side can pick up where the other left off. Transcend Retail allows dealers to carry the Mercedes-Benz luxury experience into every stage of the digital purchase.

“Luxury buyers expect the same level of care online as they receive in the showroom and they expect the two to work as one,” said Faraaz Ghauri, Vice President of Digital Retail at NETSOL Technologies, Inc. “Being approved by Mercedes-Benz USA gives its dealers a platform that keeps every deal moving in one place, from the first click to the signed contract.”

“We look forward to working closely with Mercedes-Benz dealerships to deliver the experience their customers expect from the brand,” he added.

To learn more about Transcend Retail, visit our page:
https://netsoltech.com/products/digital-retail

About NETSOL Technologies
NETSOL Technologies delivers state-of-the-art solutions for asset finance, leasing and digital automotive retail, serving automotive and equipment OEMs, dealerships, auto captives and financial institutions across over 30 countries. Since its inception in 1997, NETSOL has been at the cutting edge of technology, pioneering innovations with its asset finance solutions, and today leverages advanced AI and cloud services to meet the complex needs of the global market. Renowned for its deep industry expertise, customer-centric approach and commitment to excellence, NETSOL fosters strong partnerships with its customers, ensuring their success in an ever-evolving landscape. With a rich history of innovation, ethical business practices and a focus on sustainability, NETSOL is dedicated to empowering businesses worldwide, securing its position as the trusted partner for leading firms around the globe.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the company’s products and services, expectations for future operations, and other statements that are not historical facts. These forward-looking statements may be identified by terminology such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “projects,” “targets,” and similar expressions. These statements are not guarantees of future performance and are subject to a number of risks, uncertainties, and assumptions that are difficult to predict. Factors that could cause actual results to differ materially include, but are not limited to, the timing of customer go-lives and contract renewals, the rate of adoption of AI-enabled product capabilities, foreign currency volatility, and other factors discussed in NETSOL’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. NETSOL undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investor Relations Contact:
Investor Relations
(818) 222-9195
investors@netsoltech.com